Shares of Beam Therapeutics Inc. (BEAM) have rallied 27.3% in the past three months compared with the industry’s increase of 9.8%.Beam’s pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases.The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, for the treatment of sickle cell disease (SCD). The c ...

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam The ...

Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | --- | --- | --- | |-----------------------------------------|-------------------|-----------------------------------------------------| | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common Stock, par value $0.01 per share | BEAM | Nasdaq Global Select Market | This Quarterly Report on Form 10-Q ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------|--------|------------|------------|-------|-------|-------|-------|-------|-------|-------|--------------|----------------|----------------------------|-------|-------|----------------------------------------|-------|------------------------| | Commercial | | paper | | | | | | | | $ | Amortized \n | Cost \n578,813 | Gross Unrealized Gains \n$ | 72 | $ | Gross Unrealized Lo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 81-5238376 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 238 Main Street Cambridge, MA 02142 (Address of principal executive of ices) (Zip Code) Registrant's telephone number, including area code: (857) 327-8775 Securities registered pursuant to Section 12(b) of the Act: (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Expenses and Compensation - Research and development expenses increased by $25.4 million due to additional stock-based compensation from more stock options and restricted stock units granted to employees[170] - General and administrative expenses increased by $30.6 million, primarily due to a $15.4 million increase in stock-based compensation and a $10.9 million increase in personnel-related costs[171] Income and Investments - The company recorded $23.9 million of other income related to the change in fair value of success payment liabilities, compared to $1.0 million of expense in the previous year[174] - Other income from non-controlling equity investments was $20.2 million, driven by changes in the value of investments in Prime and Verve[174] - The company recorded $18.9 million of other income related to the change in fair value of contingent consideration liabilities due to updated project timelines[174] - Interest and other income increased to $15.3 million, primarily due to higher interest income from increased market rates[174] Revenue and Payments - The company received $300.0 million in upfront payment from the Pfizer Agreement for in vivo base editing programs[178] - The company sold 3,908,289 additional shares under the amended Sales Agreement, generating $322.0 million in gross proceeds[178] - The company received $25.0 million as the First Anniversary Payment under the Apellis Agreement in June 2022[178] - Net cash provided by operating activities for the year ended December 31, 2022 was $22.5 million, primarily driven by the collection of collaboration receivables of $300.0 million related to the Pfizer Agreement[180] - Net cash used in operating activities for the year ended December 31, 2021 was $66.3 million, primarily due to a net loss of $370.6 million and an increase in collaboration receivable of $300.0 million[180] Future Financial Commitments - The company may owe Harvard and Broad Institute success payments of up to an additional $90.0 million each, contingent upon future events[185] - The company agreed to pay Guide's former stockholders and optionholders up to an additional $100.0 million in technology milestone payments and $220.0 million in product milestone payments, payable in common stock[185] - The company leases certain assets with aggregate future minimum commitments of $268.0 million for office and laboratory leases and $2.5 million for equipment leases as of December 31, 2022[185] - The company may be required to make milestone payments to former stockholders and optionholders of Guide in the form of common stock based on the achievement of certain product and technology milestones, with payments accounted for under ASC 480 and contingent consideration liabilities carried at fair value estimated using a probability-based model[190] - The estimated fair value of contingent consideration liabilities is determined using probability-adjusted discounted cash flow models, with significant changes in probabilities of success or milestone timing potentially resulting in significantly higher or lower fair value measurements[190] Cash and Investments - As of December 31, 2022, the company had $1.1 billion in cash, cash equivalents, and marketable securities[179] - The company had cash, cash equivalents, and marketable securities totaling $1.1 billion as of December 31, 2022, with primary market risk exposure related to interest rate sensitivity[196] - The company believes an immediate 10% change in interest rates would not have a material effect on the fair market value of its investment portfolio due to the short-term duration and low-risk profile of its investments[196] - The company is not currently exposed to significant foreign currency exchange rate risk but may face increased risk from future contracts with vendors located outside the United States[196] - Inflation has not had a material effect on the company's financial statements, but future operations may be adversely affected by rising labor, research, manufacturing, and development costs[196] Leases and Accounting - The company assesses whether contracts entered into on or after the effective date contain a lease based on criteria such as the use of a distinct identified asset, the right to economic benefits, and the right to direct the use of the asset[194] - Leases are classified as either finance leases or operating leases, with finance leases meeting specific criteria such as transfer of ownership, purchase options, or lease term covering a major part of the asset's useful life[195] Future Financial Needs - The company expects to finance its cash needs through equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements, as it does not have any committed external source of capital[184] - The company's operating expenses are expected to increase substantially as it advances clinical trials, research programs, and preclinical development of product candidates[183] Investments and Write-Downs - The company's investment in Orbital has been written down to zero as of December 31, 2022, under the equity method of accounting[189]

| --- | --- | |-------|-------| | | | | | | | | | | | | Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinical studies and research and development programs, including the initiation and progress of clinical trials, including our BEACON trial and our BEAM-201 tr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-5238376 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-5238376 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-5238376 (State or other jurisdiction ...